Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib to Reverse Immunotherapy Resistance in TNBC
NCT06731153Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Dec 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ivarmacitinib in triple-negative breast cancer (TNBC) (3 arms), sponsored by Fudan University. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 21 days and 2 more. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06731153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731153.